Roger Adsett

Mr. Adsett currently serves as Chief Operating Officer of Insmed, a position he has held since November 2019 after serving as Chief Commercial Officer from 2016 to 2019. In these roles, he has overseen commercial strategy and execution, operational excellence, and enterprise-wide growth initiatives. He played a central role in building Insmed’s global commercial organization and supporting the launch and growth of ARIKAYCE® and BRINSUPRI®, establishing Insmed as a fully integrated commercial biopharmaceutical company. Prior to Insmed, Mr. Adsett held a series of senior leadership positions at Shire from 2005 to 2016, where he was responsible for global commercial operations across six specialty and two rare-disease brands. Earlier in his career, Mr. Adsett spent 11 years at AstraZeneca, where he held a variety of commercial leadership roles, including as marketing director for the U.S. launch of NEXIUM®, a blockbuster therapy for gastroesophageal reflux disease, and as global brand director for SYMBICORT®, a leading treatment for asthma and chronic obstructive pulmonary disease. Prior to Astra Zeneca, he spent three years at Accenture. Roger also served on the Board of Directors of Landos Biopharma, Inc. from March 2022 until its acquisition by AbbVie in May 2024, where he contributed to the company’s governance and strategic direction as a member of the Audit Committee.

Mr. Adsett holds a Master of Business Administration from the Wharton School at the University of Pennsylvania and a bachelor’s degree in English and economics from Bucknell University.